Side effects and adverse events
A three-question triage
- Is it systemic or local? A finding confined to the injection site is managed differently from one that involves the whole patient.
- Is it dose-related? Symptoms that appear after an escalation and settle before the next dose usually respond to slowing the ladder.
- Is it in the expected profile at all? Anything outside the described profile of the agent should stop administration until it is explained.
GLP-1 and dual-agonist therapy
| Finding | Expected? | Action |
|---|---|---|
| Nausea, early satiety | Very common; peaks in the days after an escalation and settles | Smaller meals, slow the ladder, extend the interval before the next step |
| Constipation or diarrhoea | Common through titration | Hydration and fibre first; hold escalation until bowel habit stabilises |
| Vomiting with poor intake | Not expected to persist | Hold the dose, assess hydration and renal function, resume lower |
| Severe or radiating abdominal pain | Not expected | Stop and evaluate urgently for pancreatitis or biliary disease |
| Rapid resting heart-rate rise | Small increases are described | Evaluate if sustained or symptomatic |
| Hypoglycaemia | Uncommon alone; expected with insulin or a sulfonylurea | Review concurrent agents and adjust the background regimen |
| Vision change in a diabetic patient | Not expected | Refer — rapid glycaemic improvement can worsen retinopathy |
| Neck mass, hoarseness, dysphagia | Not expected | Stop and refer; review the thyroid C-cell contraindication |
Peptide and secretagogue therapy
| Finding | Expected? | Action |
|---|---|---|
| Transient flushing or head rush after injection | Described with several secretagogues; minutes, not hours | Observe; consider dosing at night and reviewing injection speed |
| Water retention, joint aching, carpal tunnel symptoms | Dose-related with GH secretagogues | Reduce dose; persistent symptoms warrant reassessment of therapy |
| Numbness or tingling in the hands | Not expected to persist | Reduce or hold and evaluate |
| Fatigue or blood-glucose drift | Reported with some agents | Check fasting glucose and HbA1c; reassess suitability |
| Rash or urticaria away from the injection site | Not expected | Stop, treat as a hypersensitivity reaction, do not rechallenge without review |
| Fever, chills, or malaise within hours of a dose | Not expected | Stop, quarantine the vial and lot, evaluate for infection, notify the pharmacy |
Injection-site findings
A small wheal, brief stinging, or a coin-sized area of redness that fades within a day is a local reaction and generally needs nothing beyond site rotation. Escalate when erythema spreads, the area becomes warm and indurated, pain increases after 48 hours, there is drainage, or the patient develops fever. Recurrent nodules at the same site usually mean rotation has lapsed rather than a problem with the preparation.
Stop and escalate immediately
- Airway compromise, facial or tongue swelling, or generalised urticaria — treat as anaphylaxis and activate emergency services.
- Fever, rigors, or hypotension within hours of administration — evaluate for bloodstream infection and preserve the vial and lot.
- Severe epigastric pain radiating to the back, with or without vomiting — evaluate for pancreatitis.
- Right-upper-quadrant pain with fever or jaundice — evaluate for cholecystitis or choledocholithiasis.
- Spreading erythema, fluctuance, or purulence at an injection site — evaluate for cellulitis or abscess.
- New neurological deficit, syncope, or chest pain following a dose — evaluate before any further administration.
Reporting and documentation
Preserve the evidence
Quarantine the vial rather than discarding it, and record the lot number, beyond-use date, reconstitution date and diluent, and storage history. If a cold-chain excursion is possible, note the duration and temperature. Photographs of the vial, the label, and any affected site are frequently the difference between a resolvable investigation and an inconclusive one.
Where it goes
- Report to FDA MedWatch for any serious adverse event.
- Notify the dispensing pharmacy so the lot can be reviewed and, if needed, quarantined.
- Preparations from a 503B outsourcing facility carry mandatory federal adverse event reporting for the facility; 503A obligations are set by the state board.
- Document in the chart the same day, including the decision to hold, reduce, or stop.
Orders placed through the network keep the fulfilling pharmacy, the lot, and the shipment on the order record, so the sourcing detail needed for a report is retrievable without calling around.
Frequently asked
When should a GLP-1 dose be held rather than reduced?
Hold when the patient cannot maintain oral intake, has persistent vomiting with signs of dehydration, or presents with severe abdominal pain suggestive of pancreatitis or biliary disease. Reduce, rather than hold, for tolerable nausea that improves between doses.
Is injection-site redness a reason to stop therapy?
A small, self-limited area of erythema or itching within a day of injection is a common local reaction and usually resolves with site rotation. Spreading erythema, warmth, induration, purulence, fever, or pain that worsens after 48 hours suggests infection and needs evaluation.
How are adverse events involving compounded preparations reported?
Report to FDA MedWatch and notify the dispensing pharmacy, retaining the vial, label, and lot number. Preparations from a 503B outsourcing facility carry mandatory federal reporting obligations for the facility; 503A reporting requirements are set at state level.
What information should be captured before contacting the pharmacy?
Compound and strength, lot number and beyond-use date, reconstitution date and diluent, storage history, dose and time administered, onset and description of the reaction, and any photographs of the vial or the site.